Abbott Laboratories stock steadies as FDA clears dual glucose-ketone sensor and CEO plans share sale
Published on 08/26/2026 at 08:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories (US0028241000) stock recently changed hands at $116.13 at the close on August 25, 2026, as investors digested a new U.S. regulatory approval for a dual glucose-ketone sensor and a fresh filing detailing CEO Robert Ford's plan to sell up to 398,832 shares of company stock.
Stock holds close to consensus targets
According to a detailed market quote overview, Abbott Laboratories shares finished regular trading at $116.13 on August 25, 2026, before easing to $115.26 in after-hours dealings that evening. A separate performance snapshot cited an earlier session open at $116.70 and implied a market capitalization of $201.94 billion for the healthcare group on August 25, 2026, underscoring the company's scale in the global medical-technology and diagnostics sector.
Several recent analyst and data summaries point to a broadly constructive view on the valuation backdrop. One consensus compilation highlighted an average 12-month price target of $118.67, only modestly above where the shares most recently traded, while another recent cross-check referenced a consensus objective of $119.50 for Abbott Laboratories stock in the current research cycle. A separate fair-value framework using a GF Value model cited an intrinsic value estimate of $132.55 per share versus spot prices in the mid-$110 range, implying upside potential from current levels under that methodology.
Recent institutional activity has mirrored that cautiously positive tone. One institutional holding report described a major asset manager lifting its Abbott position by 21.1% in the second quarter of 2026, acquiring 248,360 additional shares and taking its total stake to 1.42 million shares valued at $129.2 million at the time of the filing. Other fund disclosures show some managers trimming exposure, but aggregated analyst coverage still classifies Abbott Laboratories stock as a moderate buy, with the bulk of ratings in the buy or strong-buy category.
Q2 2026 results beat and guidance raised
From an operating perspective, Abbott Laboratories' latest reported quarter provides the fundamental context behind those views. In its second-quarter 2026 results, the company reported adjusted earnings per share of $1.31, exceeding the prevailing consensus estimate by $0.03 per share for the period. The same update showed total revenue of $12.59 billion in the quarter, an increase of 13% compared with the prior-year second quarter, driven by growth across diagnostics, medical devices and nutrition.
Management also sharpened its full-year outlook on the back of that performance. In the July 2026 reporting cycle, Abbott reaffirmed comparable sales growth guidance of 6.5% to 7.5% for 2026, signaling confidence in continued demand across its major franchises. At the same time, it raised the full-year 2026 adjusted EPS guidance range to $5.45 to $5.60, lifting the midpoint from earlier expectations and reinforcing the earnings-growth narrative that many investors track in large-cap healthcare names.
Cash returns to shareholders remain part of the investment case. A recent dividend announcement confirmed a quarterly payout of $0.63 per share, which at recent share prices translates into a forward dividend yield of roughly 2.2% on an annualized basis. Historically, Abbott has combined this dividend policy with periodic share repurchases as balance-sheet capacity allows, creating an ongoing capital-return stream alongside organic growth initiatives.
FDA clears dual glucose-ketone sensing device
A key catalyst for Abbott Laboratories stock as of late August 2026 is the authorization of a new wearable sensor that measures both glucose and ketone levels for people living with diabetes. A targeted regulatory update on August 25, 2026, detailed that the U.S. Food and Drug Administration cleared Abbott's Libre Duo 10 Day system, described as the first continuous device authorized by the agency to track both blood sugar and ketone metrics in a single wearable platform.
The Libre Duo 10 Day sensor is designed for a 10-day wear period and is indicated for adults and children aged 2 years and older living with diabetes, according to the FDA-focused report. The sensor fits within Abbott's broader FreeStyle Libre and continuous glucose monitoring portfolio, which has been a major growth engine in recent years. By giving patients and clinicians visibility into both glucose control and ketone buildup, the technology aims to help users detect patterns that could signal an elevated risk of diabetic ketoacidosis and adjust treatment plans earlier.
Sector coverage has emphasized that this dual-parameter design differentiates Abbott's offering in an increasingly competitive continuous glucose monitoring landscape. Some comparative commentary contrasted Abbott's latest innovations with rival systems from other device makers, noting that the added ketone capability could support premium pricing and deeper integration into digital health ecosystems over time, especially as payers and providers focus on outcomes-based care in diabetes management.
Settlement over infant-formula claims
Alongside the device news, Abbott Laboratories continues to address legacy legal issues stemming from its infant-formula business. A recent legal and corporate-news summary reported that Abbott agreed to pay $670 million to resolve roughly 2,000 claims alleging that certain specialty formulas for premature infants were associated with an increased risk of necrotizing enterocolitis, a severe bowel disease. The settlement was described as resolving a substantial portion of outstanding cases without an admission of liability by the company.
The same cluster of reporting highlighted a separate proposed settlement in securities litigation connected to the company's 2022 powdered infant-formula recall and production disruptions at a plant in Sturgis, Michigan. In that investor lawsuit, Abbott Laboratories agreed in principle to pay $88.5 million to settle allegations that it misrepresented the severity of the recall and its operational impact. Plaintiffs asked a U.S. district court for preliminary approval following the company's broader settlement announcement on the infant claims.
While the combined settlement amounts are material in absolute terms, they are measured against a business generating more than $12 billion in quarterly revenue and guided to earn at least $5.45 per share on an adjusted basis in 2026. Analysts examining the numbers have generally framed the settlements as financially manageable, particularly when spread across multiple periods, though they continue to monitor any remaining litigation exposure and potential changes in regulatory oversight of infant-nutrition facilities.
CEO's planned sale of 398,832 shares
Another development in late August 2026 is the disclosure that Abbott Laboratories chairman and CEO Robert B. Ford has filed a notice of intent to sell a significant block of company shares under Rule 144. A detailed filing summary from August 25, 2026, explained that Ford submitted a notice covering a proposed sale of up to 398,832 shares of Abbott common stock, with transactions to be executed through a designated financial institution beginning on or after August 25, 2026.
The Rule 144 notice states that the shares to be sold are expected to be acquired via the cash exercise of stock options before being sold into the market. The document lists UBS Financial Services, Inc. as the broker managing the planned transactions and provides a Weehawken, New Jersey office address for the firm. Rule 144 structures of this kind are common among senior executives at large U.S. companies, enabling them to diversify personal holdings while disclosing prospective sales volumes and timing windows to the market in advance.
For investors, the planned sale underscores the scale of stock-based compensation at Abbott Laboratories and the degree to which leadership remuneration is tied to long-term share performance. Some market participants may watch trade data in coming weeks to see how quickly Ford's broker executes the authorized share sales and whether the volumes create any temporary technical pressure on Abbott Laboratories stock, although the company's average daily trading volume and $200-billion-plus market capitalization help absorb such flows over time.
Analyst consensus and valuation context
The backdrop to these company-specific developments is a largely supportive analyst and valuation profile. Multiple recent coverage digests show that, across about two dozen research firms, Abbott Laboratories stock carries an average rating described as moderate buy. Within that distribution, four analysts reportedly rate the shares as hold, while 19 list them as buy and three assign a strong-buy rating, illustrating a clear tilt toward positive recommendations among professionals covering the name.
Price-target data from the same sources indicate that the average analyst objective currently ranges from $118.67 to $121.50 for the next 12 months, depending on the specific compilation. Measured against the most recent close of $116.13 on August 25, 2026, the lower bound of that range implies upside of about 2.2%, while the $121.50 consensus would represent an advance of roughly 4.6% if achieved. Those expectations sit below the $132.55 GF Value estimate cited in one fair-value model, highlighting a spread between analyst targets and some quantitative valuation tools.
Dividend investors also track Abbott's payout metrics in assessing total-return potential. With a quarterly dividend of $0.63 per share in place and the share price in the mid-$110 range, the indicated yield of about 2.2% complements prospective earnings growth and re-rating potential. For income-focused portfolios, that combination of yield, dividend history and exposure to secular healthcare trends supports the argument for continued inclusion of Abbott Laboratories stock alongside other large-cap medical-technology and diagnostics peers.
FreeStyle Libre and continuous monitoring products
Within Abbott Laboratories' portfolio, continuous glucose monitoring products remain central to the growth story and investor narrative. The FreeStyle Libre range of sensors and readers, along with the newly authorized Libre Duo 10 Day device, target a global diabetes population numbering in the hundreds of millions. Recent sector updates have emphasized growing uptake of sensor-based monitoring as payers and clinicians shift away from traditional finger-stick glucose testing toward more granular, real-time data streams.
The FDA's authorization of a dual glucose-ketone sensor reinforces Abbott's competitive positioning in this segment. By adding ketone monitoring to glucose tracking, Libre Duo 10 Day aims to improve detection of metabolic deterioration that could precede serious complications in people with diabetes, particularly those using insulin. As Abbott leverages this capability across software platforms and integrates readings into mobile applications and clinical dashboards, the company has an opportunity to deepen relationships with healthcare systems that prioritize proactive disease management.
Closing view on Abbott Laboratories stock
Abbott Laboratories stock most recently closed at $116.13 on August 25, 2026, in New York Stock Exchange trading, with an after-hours indication of $115.26 that evening, reflecting investor reactions to the latest product approvals, legal settlements and executive share-sale disclosures against a backdrop of raised 2026 EPS guidance and double-digit quarterly revenue growth.
Read more
Investor Relations
Fact box
Company: Abbott Laboratories Inc.
ISIN: US0028241000
Ticker: ABT
Exchange: NYSE
Price (as of August 25, 2026, 4:02 p.m. ET): $116.13 USD
Market cap: $201.94 billion (as of August 25, 2026)
Sector / Industry: Health care / Medical devices and diagnostics
Index membership: S&P 500
